AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Oncophage yields promising immunological results in melanoma and colorectal cancer trials.(Brief Article)
2002 MAY 8 - (NewsRx.com & NewsRx.net) -- Antigenics, Inc., (AGEN) announced interim results from phase II trials evaluating Oncophage (HSPPC-96), the company's personalized cancer vaccine, in the treatment of both advanced melanoma and colorectal cancer.
Described in an oral presentation at the 93rd annual meeting of the American Association for Cancer Research, the data show that in these patients, treatment with Oncophage can induce significant expansion of cancer-specific immune responses, and that the induction mechanism is the same for both cancers.
"We have seen very similar immunological responses to Oncophage treatment in kidney cancer, melanoma and colorectal cancer," said Jonathan Lewis, MD, PhD, chief medical officer of Antigenics, Inc. "That the vaccine employs the same mode of action regardless of cancer type provides a very strong basis for continued investigation of the use of Oncophage across a broad array of cancers."
Oncophage is a personalized cancer vaccine tailored for each patient. Derived from each individual's tumor, it contains complexes of heat shock proteins - the "antigenic fingerprint" of the patient's particular cancer. The vaccine is designed to reprogram the body's immune system to target and destroy only cancer cells bearing this fingerprint. Oncophage is intended to leave healthy tissue ...
- Antigenics announces that immunological data from Phase II melanoma and...
- News wire article from: Asia Africa Intelligence Wire October 1, 2003 700+ words
...cancer vaccine Oncophage (HSPPC-96...melanoma and colorectal cancer were published...melanoma and colorectal cancer. Researchers...response to Oncophage vaccination...patients with colorectal cancer) demonstrated...
- Phase II Results of Antigenics' Oncophage Cancer Vaccine in Colorectal Cancer...
- Press release article from: Business Wire August 19, 2003 700+ words
...personalized cancer vaccine Oncophage(R) (HSPPC-96...patients with metastatic colorectal cancer were published as...patients who received Oncophage demonstrated significant...gastric cancers. Oncophage has been granted fast...kidney cancer. About Colorectal Cancer Together, ...
- Antigenics Announces that Immunological Data from Phase II Melanoma and...
- Press release article from: Business Wire October 1, 2003 700+ words
...cancer vaccine Oncophage(R) (HSPPC...melanoma and colorectal cancer were published...response to Oncophage vaccination...patients with colorectal cancer) demonstrated...potential of Oncophage as a therapy...melanoma and colorectal cancer. Such statements...
- Phase II results of Antigenics' Oncophage cancer vaccine in colorectal cancer...
- News wire article from: Asia Africa Intelligence Wire August 19, 2003 700+ words
...personalized cancer vaccine, Oncophage (HSPPC-96) in patients with metastatic colorectal cancer were published as...patients, who received Oncophage, demonstrated significant...patients with stage IV colorectal cancer that had spread to...produce the personalized Oncophage ...
- Data from Phase I Trial of Oncophage Cancer Vaccine in Pancreatic Cancer...
- Press release article from: Business Wire September 22, 2003 700+ words
...Patients Receiving Oncophage; Findings From Phase...Aroplatin(TM) in Colorectal Cancer Also Presented Antigenics...personalized cancer vaccine Oncophage(R) (HSPPC-96...stage development, Oncophage has been granted fast...Data on Aroplatin in Colorectal Cancer Also Presented ...
- Data from Phase I trial of oncophage cancer vaccine in pancreatic cancer...
- News wire article from: Asia Africa Intelligence Wire September 22, 2003 700+ words
...manufacture of personalized Oncophage vaccines was feasible and...used to produce personalized Oncophage vaccine for each patient...surgery, study subjects began Oncophage treatment, which consisted...of Aroplatin in metastatic colorectal cancer refractory to standard therapy...
- Antigenics Enrolls First Patient in Phase II Study of Aroplatin in Colorectal...
- Press release article from: Business Wire July 18, 2002 700+ words
...II studies. About Colorectal Cancer The American Cancer...line treatments for colorectal cancer in the United States...the treatment of colorectal cancer that is refractory...portfolio includes Oncophage(R), a personalized...
- Antigenics Presents Positive Oncophage Interim Survival Data at ASCO.
- Newspaper article from: Wireless News June 3, 2009 700+ words
...lower risk of death when treated with Oncophage (vitespen) cancer vaccine compared...and these interim results show that Oncophage has a real promise of improving survival...Dr. Wood. "Based on these results, Oncophage offers these patients a potential treatment...
- Oncophage cancer vaccine clinical findings announced.
- Newspaper article from: Biotech Business Week July 5, 2004 700+ words
...s investigational cancer vaccine Oncophage (HSPPC-96). Demographic data...the company's phase III trial of Oncophage in renal cell carcinoma (the most...epidemiology of this disease." Oncophage, Antigenics' lead product in development...
- Oncophage(R) Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by...
- Press release article from: Business Wire May 21, 2007 700+ words
...Risk Kidney Cancer Patients Who Received Oncophage Antigenics Presents Updated Phase 3 Results...investigational therapeutic cancer vaccine Oncophage([R]) (vitespen). The end-of...intermediate risk for disease recurrence, Oncophage demonstrated a clinically significant...
Source: HighBeam Research, Oncophage yields promising immunological results in melanoma and...